» Articles » PMID: 25803862

High Peripheral Blood Th17 Percent Associated with Poor Lung Function in Cystic Fibrosis

Overview
Journal PLoS One
Date 2015 Mar 25
PMID 25803862
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

People with cystic fibrosis (CF) have been reported to make lung T cell responses that are biased towards T helper (Th) 2 or Th17. We hypothesized that CF-related T cell regulatory defects could be detected by analyzing CD4+ lymphocyte subsets in peripheral blood. Peripheral blood mononuclear cells from 42 CF patients (6 months-53 years old) and 78 healthy controls (2-61 years old) were analyzed for Th1 (IFN-γ+), Th2 (IL-4+), Th17 (IL-17+), Treg (FOXP3+), IL-10+ and TGF-β+ CD4+ cells. We observed higher proportions of Treg, IL-10+ and TGF-β+ CD4+ cells in CF adults (≥ 18 years old), but not children/adolescents, compared with controls. Within the CF group, high TGF-β+% was associated with chronic Pseudomonas aeruginosa lung infection (p < 0.006). We observed no significant differences between control and CF groups in the proportions of Th1, Th2 or Th17 cells, and no association within the CF group of any subset with sex, CFTR genotype, or clinical exacerbation. However, high Th17% was strongly associated with poor lung function (FEV1 % predicted) (p = 0.0008), and this association was strongest when both lung function testing and blood sampling were performed within one week. Our results are consistent with reports of CF as a Th17 disease and suggest that peripheral blood Th17 levels may be a surrogate marker of lung function in CF.

Citing Articles

in cystic fibrosis children and adolescents: overall survival and immune alterations.

Shmarina G, Pukhalskaya D, Shmarin V, Semykin S, Avakyan L, Krasovsky S Front Cell Infect Microbiol. 2024; 14:1374318.

PMID: 39011515 PMC: 11246859. DOI: 10.3389/fcimb.2024.1374318.


Abnormal functional lymphoid tolerance and enhanced myeloid exocytosis are characteristics of resting and stimulated PBMCs in cystic fibrosis patients.

Gaudin C, Ghinnagow R, Lemaire F, Villeret B, Sermet-Gaudelus I, Sallenave J Front Immunol. 2024; 15:1360716.

PMID: 38469306 PMC: 10925672. DOI: 10.3389/fimmu.2024.1360716.


Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors).

Bonifacio L, Ramacciotti E, Agati L, Vilar F, Silva A, Junior P Rev Soc Bras Med Trop. 2023; 56:e0565.

PMID: 37075454 PMC: 10109354. DOI: 10.1590/0037-8682-0565-2022.


Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy.

Westholter D, Raspe J, Uebner H, Pipping J, Schmitz M, Strassburg S Front Immunol. 2023; 14:1107437.

PMID: 36875141 PMC: 9978140. DOI: 10.3389/fimmu.2023.1107437.


The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation.

Caverly L, Riquelme S, Hisert K Clin Chest Med. 2022; 43(4):647-665.

PMID: 36344072 PMC: 10224747. DOI: 10.1016/j.ccm.2022.06.007.


References
1.
Fazekas de St. Groth B, Zhu E, Asad S, Lee L . Flow cytometric detection of human regulatory T cells. Methods Mol Biol. 2011; 707:263-79. DOI: 10.1007/978-1-61737-979-6_17. View

2.
Dubin P, McAllister F, Kolls J . Is cystic fibrosis a TH17 disease?. Inflamm Res. 2007; 56(6):221-7. DOI: 10.1007/s00011-007-6187-2. View

3.
Schadenberg A, Vastert S, Evens F, Kuis W, van Vught A, Jansen N . FOXP3+ CD4+ Tregs lose suppressive potential but remain anergic during transient inflammation in human. Eur J Immunol. 2011; 41(4):1132-42. DOI: 10.1002/eji.201040363. View

4.
Knutsen A, Slavin R . Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis. Clin Dev Immunol. 2011; 2011:843763. PMC: 3095475. DOI: 10.1155/2011/843763. View

5.
Mueller C, Braag S, Keeler A, Hodges C, Drumm M, Flotte T . Lack of cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses. Am J Respir Cell Mol Biol. 2010; 44(6):922-9. PMC: 3135852. DOI: 10.1165/rcmb.2010-0224OC. View